Skip to main content

Select Drug Profiles

The View from Washington: Healthcare Reform

Practice Management

Applying Evidence for Medical Technologies: Closing the Gap between R&D and Decision Maker Needs

Stakeholder Perspective

Policy Considerations in Evidence-Based Coverage Decisions

by F. Randy Vogenberg, PhD, FASHP

Practice Management

Biosimilars Policy Forum: Perspectives on Safety and Efficacy of Future Products

F. Randy Vogenberg, PhD, FASHP

Practice Management

The Working Patient with Cancer: Implications for Payers and Employers

Grant D. Lawless, BSPharm, MD, FACP

Stakeholder Perspective

Data-Driven Benefit Design for Chronic Diseases

by Gary M. Owens, MD

Practice Management

Lower Copay and Oral Administration: Predictors of First-Fill Adherence to New Asthma Prescriptions

Zackary Berger, MD, PhD, William Kimbrough, MD, Colleen Gillespie, PhD, Joseph A. Boscarino, PhD, MPH, G. Craig Wood, MS, Zhengmin Qian, MD, PhD, J. B. Jones, PhD, MBA, Nirav R. Shah, MD,MPH

Stakeholder Perspective

Medication Adherence: Is Lower Copay the Best Strategy to Improve Care and Reduce Costs?

by Ronald A. Lyon, MS

Practice Management

Payer Perspectives on Healthcare Reform

Peyton Howell, MHA, Gene Reeder, RPh, PhD, Timothy S. Regan, BPharm, RPh, CPh

Original Research

Use Pattern and Off-Label Use of Atypical Antipsychotics in Bipolar Disorder, 1998-2002

Jeffery A. Demland, MS, Yonghua Jing, BPharm, PhD, Christina M. L. Kelton, PhD, Jeff Jianfei Guo, BPharm, PhD, Hong Li, PhD, Patricia R. Wigle, PharmD

Stakeholder Perspective

Health Plans’ Approaches to Managing Appropriate Use of Antipsychotic Drugs

by Renee Rizzo Fleming, RPh, MBA

Workplace Wellness and Disease Prevention: Focus on Chronic Obstructive Pulmonary Disease

COPD Management in a Value-Based Healthcare System

The Economic Burden of COPD in the Workplace

Page 238 of 244
Results 2371 - 2380 of 2434